A significant number of medical products critical to everyday procedures, lifesaving surgeries, and public health preparedness efforts are made outside of the United States. It is important for both Congress and the Administration to understand the complexities of the U.S. healthcare supply chain, so tariffs and trade policies do not create unintentional supply chain disruptions and product shortages that would negatively impact healthcare providers and the patients they treat.

Recent News

Tariffs
GA Alert
USTR Finalizes Significant Tariff Increases On PPE & Syringes
9/13/2024
Tariffs
GA Alert
USTR Further Delays Final Determination On China Tariff Increases; Announcement Due In Coming Days
8/30/2024
Tariffs
GA Alert
USTR Extends Many COVID-19 Chinese Tariff Exclusions
5/24/2024
Tariffs
GA Alert
USTR Issues Additional Details of Proposed Tariff Increases on PPE & Syringes From China
5/22/2024
Tariffs
GA Alert
Administration Proposes Increased Tariffs On $18B Of Chinese Imports, Including Syringes & PPE
5/14/2024
Tariffs
Advocacy Letter
Letter to Ambassador Katherine Tai Re: Tariffs, Docket Number 2023-28770
2/21/2024

HIDA has long advocated for the free flow of goods in the medical supply chain. Since 2018, HIDA has repeatedly engaged the Office of the U.S. Trade Representative and Congress with comment, testimony, and advocacy intended to lower the cost of medical products in the United States, and to exclude from tariffs categories of medical products that are vital to patient health.

Contact

Christina Lavoie

Christina Lavoie
Director of Policy
703-838-6138
lavoie@hida.org